ArticleMolecular biotechnology2026
Phytonutrients as a Defensive Barrier Against G Ectodomain Fusion in Chandipura Virus Infection.
Article in Molecular biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Comprehensive Network pharmacology and in vitro investigation of L-mimosine: unveiling multi-targeted therapeutic potential against breast cancer.BMC complementary medicine and therapies · 2025Article
- Potential Benefits of In Silico Methods: A Promising Alternative in Natural Compound's Drug Discovery and Repurposing for HBV Therapy.Pharmaceuticals (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Viruses, microscopic menace that transcends time leaving its mark on every era have been silent predators since the dawn of civilization, evolving with us and shaping our history. Chandipura virus (CHPV), a potent member of the Rhabdoviridae family poses a significant threat in India with rapid neuroinvasive potential leading to fatal encephalitis, particularly in children. Given the scarcity of research, our study consolidates critical information regarding its lifecycle, fusion process, and reviewed the LRP1 and GRP78 as CHPV target receptors. With no FDA-approved drugs currently available for CHPV prevention, our research focuses on identifying potential molecules that can disrupt the virus at its most critical juncture, the fusion stage. The results derived from compounds screening indicated Silibinin, 3-(2,3-Dihydroxy-3-Methylbutyl)-6-Hydroxy-2-[(1E,5E)-3,4,10-Trihydroxyundeca-1,5-Dienyl] Benzaldehyde, Budmunchiamine L5, and L4 as a leading molecule may efficaciously inhibit G ectodomain fusion. By analyzing pharmacokinetic properties through radar graph, outcomes support the nomination of four compounds as potential inhibitory molecules and ensure they possess the optimal balance of drug-like characteristics. Working with the CHPV presents significant challenges, making the in silico parameters crucial in guiding future research. Our study sought to pioneer the discovery of therapeutic molecules against the CHPV, providing a foundational framework for developing effective antiviral strategies.
Indexed as
Identifiers
39998775What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.